8-HYDROXYGUANOSINE manufacturers
- 8-Hydroxyguanosine
-
- $73.00 / 5mg
-
2026-02-02
- CAS:3868-31-3
- Min. Order:
- Purity: 96.67%
- Supply Ability: 10g
- 8-HYDROXYGUANOSINE
-
- $1.00 / 1KG
-
2024-08-14
- CAS:3868-31-3
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 20T
|
| | 8-HYDROXYGUANOSINE Basic information |
| Product Name: | 8-HYDROXYGUANOSINE | | Synonyms: | 8-Oxo-D-guanosine;2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,7-dihydropurine-6,8-dione;2-amino-9-beta-d-ribofuranosylpurine-6,8(1h,9h)-dione;7,8-dihydro-8-oxo-guanosin;9h)-dione,2-amino-9-beta-d-ribofuranosyl-purine-8(1h;8-HYDROXYGUANOSINE;8-OHG;8-OH-GUO | | CAS: | 3868-31-3 | | MF: | C10H13N5O6 | | MW: | 299.24 | | EINECS: | | | Product Categories: | Carbohydrates & Derivatives;Metabolites & Impurities;Nucleotides and Nucleosides;Bases & Related Reagents;Labeling and Diagnostics Reagents;Nucleotides | | Mol File: | 3868-31-3.mol |  |
| | 8-HYDROXYGUANOSINE Chemical Properties |
| Melting point | 232-235°C | | density | 2.43±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | DMSO (Slightly), Methanol (Slightly, Heated, Sonicated) Water (Slightly, Heated,Sonicated) | | form | White to off-white powder. | | pka | 7.75±0.20(Predicted) | | color | White to Off-White | | Stability: | Hygroscopic |
| Toxicity | sce-hmn-lym 100 nmol/L MUREAV 403,223,1998 |
| | 8-HYDROXYGUANOSINE Usage And Synthesis |
| Chemical Properties | Crystalline Solid | | Uses | A marker compound indicative of DNA damage associated with mutagenesis and carcinogenesis. Can induce differentiation of Friend murine erythroleukemia cells in vitro | | Uses | It is a representative metabolite derived by the oxidation of Guanosine (G) and is regarded as a marker of oxidative stress in the cells. | | Definition | ChEBI: 8-Hydroxyguanosine is a purine nucleoside. | | Safety Profile | Mutation data reported. When heated to decomposition it emits toxic vapors of NOx. | | in vivo | 8-Hydroxyguanosine (60 mg/kg, i.p., 4 h before LPS (1 mg/kg) injected) attenuates the LPS-induced increase in serum levels of TNF-α and IL-18 in LPS-treated mice[4].
| Animal Model: | LPS-treated mice[4] | | Dosage: | 60 mg/kg | | Administration: | i.p., 4 h before LPS (1 mg/kg) injected | | Result: | Attenuated the LPS-induced increase in serum levels of TNF-α and IL-18, but was not significant for IL-6 and IL-12p70 in mice. |
| | IC 50 | Human Endogenous Metabolite |
| | 8-HYDROXYGUANOSINE Preparation Products And Raw materials |
|